atorvastatin / Generic mfg. - LARVOL DELTA

ABC-SE: A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P2 | N=126 | Completed | Sponsor: Lund University Hospital | Recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Jan 2025 | Trial primary completion date: Apr 2024 ➔ Jan 2025

Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor • CTCs • ER • HER-2

Atorvastatin modulates lipid profile, glucose transporters, and neuronal markers in the brain of diabetic mice: insights into potential neuroprotective role (EASD 2025) - "Our findings indicate that atorvastatin benefits metabolic and neuronal parameters in a T2D mouse model. The treatment partially reversed hyperglycemia-induced alterations, modulated brain lipid composition, and restored key glucose transporter and neuronal function markers in the cortex and hippocampus. These results suggest atorvastatin's potential neuroprotective role in T2D-associated brain dysfunction, possibly through lipid homeostasis and glucose metabolism regulation."

Preclinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus • CCL2 • CREB1 • NFKB1 • SLC2A1 • SLC2A3 • SLC2A4

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study. (PubMed, Ther Clin Risk Manag) - P2 | "Hypertriglyceridemia was mostly managed using atorvastatin and simvastatin. The safety data reflected satisfactory tolerability and adverse event management, supporting the involvement of a multidisciplinary disease management team in ovarian cancer care. NCT04376073."

Adverse events • Clinical • Journal • P2 data • Platinum resistant • Cardiovascular • Dermatology • Dyslipidemia • Hematological Disorders • Hypertension • Hypertriglyceridemia • Leukopenia • Neutropenia • Oncology • Ovarian Cancer • Solid Tumor • Thrombocytopenia

Cerebrovascular accidents - Unexpected complication of systemic sclerosis: A scarce case report. (PubMed, Medicine (Baltimore)) - "This case highlights a patient with SS who presented with macrovascular stenosis. This unusual presentation underscores the importance of vigilance for macrovascular involvement in SS patients presenting with neurological symptoms."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology • Ischemic stroke • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • Vasculitis

Novel Atorvastatin-eluting Microparticles Provide Neuroprotection from Cisplatin Ototoxicity (AAO-HNSF 2025) - "We identified a therapeutic range of resuspended atorvastatin and encapsulated atorvastatin into microparticles with retained bioactivity in our RSC96 cell culture model of cisplatin neurotoxicity. Our microparticles continued to release a therapeutic concentration of atorvastatin at 7 weeks. Further efforts are ongoing to further quantify atorvastatin released from our microparticles using HPLC-MS analysis to determine the full duration of drug release from a single administration."

Late-breaking abstract • Otorhinolaryngology

Drug Repurposing for Reducing the Size of Benign Thyroid Nodules: A Systematic Review (ATA 2025) - "One RCT found rosuvastatin (10 mg/day) significantly reduced MND from 16.14 to 15.42 mm, whereas higher doses of rosuvastatin and atorvastatin showed no significant effects. Metformin emerges as the most consistently effective agent for reducing benign thyroid nodule size. Statins showed modest reductions in one RCT and one prospective study, but observational data cannot establish causality. Somatostatin analogues produced variable results."

Review • Acromegaly • Endocrine Disorders

Cumulative Hepatoprotective, Antihyperlipidemic and Antioxidant Effects of Methanolic Seeds Extract of Citrullus lanatus, Cucumis melo, Cucumis sativus, and Cucurbita maxima With GC-MS Profile. (PubMed, Food Sci Nutr) - "Group I (control) rats received 5% Tween 80; Group II (Negative control) rats were given a high-fat meal with a 20% fructose solution; Groups III and IV received a combination of methanolic seed extract at a dose of 250 and 500 mg/kg, respectively, + high-fat diet/20% fructose water, while Group V (Positive control) received Atorvastatin (10 mg/kg) and Metformin (200 mg/kg) with a high-fat diet and 20% fructose. The results from GC-MS data reveal the occurrence of hexadecanoic acid methyl ester (methyl palmitate) as well as 9,12-octadecadienoic acid (linoleic acid) in abundance. The presence of these compounds might be responsible for hepatoprotective, antihyperlipidemic, and antioxidant activities."

Journal • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Simple and Highly Sensitive Liquid Chromatographic-Mass Spectrometric Method for the Determination of Itraconazole and Its Major Metabolite in Human Plasma and Its Application to a Bioequivalence Study. (PubMed, J Chromatogr Sci) - "Itraconazole (drug), hydroxyitraconazole (metabolite), and atorvastatin as internal standard were added to plasma samples. The 90% confidence intervals of the logarithmically transformed AUC0-72, AUC0-∞, and Cmax of the two formulations both for the drug and the metabolite are within the accepted levels proposed by FDA and EMA. Therefore, the presented method is suitable for bioavailability, pharmacokinetic, and bioequivalent studies in humans."

Journal

Influenza A-Induced Acute Liver Injury: A Rare Adverse Effect (ACG 2025) - "The patient's home medications include atorvastatin, carbamazepine, cyclobenzaprine, famotidine, fluoxetine, gabapentin, hydroxyzine, metformin, multivitamin, propranolol, senna, Seroquel, vitamin B1, Vivitrol. Additionally, labs from a month ago showed liver enzymes to be at baseline. These findings along with the IVA infection point towards IAV-induced ALF.Given the potential for ALI, especially in severely ill patients, routine liver enzyme testing is recommended in the management of IAV infection."

Adverse events • Autoimmune Hepatitis • Chronic Kidney Disease • Hepatology • Immunology • Infectious Disease • Inflammation • Influenza • Liver Failure • Metabolic Disorders • Respiratory Diseases

Pharmacological Approaches in Lipodystrophy: Concomitant Medication and Metreleptin Therapy Use in the Participants of LD-Lync Study (ENDO 2025) - P | "Metformin was the most commonly used antidiabetic agent, particularly in FPLD (n=101), followed by CGL (n=21), APL (n=10), and AGL (n=5)...Fenofibrate was used by 79 patients, with the highest prevalence observed in the CGL (48%) and FPLD (35%) subgroups. Statins, primarily atorvastatin (n=57) and rosuvastatin (n=25), were the most prescribed lipid-lowering agents, and were used by 100 patients overall, including 47.9% of those in the FPLD subgroup...Omega-3 derivatives were used by 53 patients (19%), while niacin and cholestyramine were used by only two patients... This study highlights the heterogeneity in pharmacological management across lipodystrophy subtypes, reflecting their diverse metabolic profiles and needs. While metreleptin remains the cornerstone therapy for generalized lipodystrophy, there is a need for novel therapeutic options to achieve improved metabolic control and optimize treatment outcomes in partial lipodystrophy."

Dyslipidemia • Lipodystrophy • Metabolic Disorders • Rare Diseases

Drug-Induced Liver Injury With Combination Semaglutide and Atorvastatin (ACG 2025) - "Oral semaglutide 3mg was started for her diabetes and increased to 7mg a month later and changed from pravastatin 40mg to atorvastatin 20mg for persistent LDL elevation...Her home medications include levothyroxine, losartan, metformin, and a multivitamin...Although rare, with the increasing popularity of GLP-1 agonists and widespread use of statins, clinicians should be aware of this potential effect and monitor hepatic function when prescribing these medications in combination.Figure: Figure 1. Trends of liver enzyme elevation following initiation of semaglutide and atorvastatin with subsequent discontinuation of semaglutide."

Cardiovascular • Diabetes • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hepatology • Hypertension • Inflammation • Liver Failure • Metabolic Disorders • Obesity • Pancreatitis • Type 2 Diabetes Mellitus

Direct analysis of pharmaceutical tablets using dielectric barrier discharge ionization-mass spectrometry: An ambient mass spectrometry approach (ACS-Fall 2025) - "The aim of the study is to quickly determine and quantify active pharmaceutical ingredients (APIs) in intact tablets, such as paracetamol, ramoril, clonazepam, icosapent ethyl, pantoprazole, atorvastatin and cholecalciferol (vitamin D3), without requiring a lot of sample preparation. The method has the potential to be used in the pharmaceutical industries for both quality control and counterfeit identification because it can identify contaminants or degradation products and differentiate between authentic and counterfeit drugs. This work advances the area of ambient mass spectrometry by highlighting the adaptability of DBDI-MS as an affordable, high-throughput tool for the direct analysis of solid pharmaceutical tablets."

Bempedoic acid in clinical practice. (ESC-WCC 2025) - "The majority had coronary artery disease (91.5%) and preserved left ventricular function (72%).The most commonly used statin was rosuvastatin (60.7%), followed by atorvastatin (33.9%)...Additionally, 7.3% were taking icosapent ethyl...ConclusionsBempedoic acid is a valuable tool for lowering LDL cholesterol and preventing cardiovascular events, especially in patients who cannot tolerate statins or do not reach target levels. Its efficacy and safety, achieving LDL reductions of around 18% demonstrated both in clinical trials and increasingly in clinical practice, as well as the possibility of taking it in a single pill with ezetimibe, position it as an important therapeutic option in the current management of dyslipidaemia."

Clinical • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • CRP

Exp5300: Treatment of Chronic Mountain Sickness (clinicaltrials.gov) - P=N/A | N=60 | Completed | Sponsor: Centre d'Expertise sur l'Altitude EXALT | Recruiting ➔ Completed

Trial completion

Assessing effectiveness of adding niosomal atorvastatin 1% ointment to topical calcineurin inhibitor treatment in non-segmantal vitiligo (EADV 2025) - No abstract available

Dermatology • Immunology • Vitiligo

Exploring topical atorvastatin hyalurosomal gel as an adjuvant for reducing systemic corticosteroid dosage: a randomized clinical trial in severe oral lichen planus patients. (PubMed, Drug Deliv Transl Res) - "ATV-Hyalugel enables a 50% corticosteroid dose reduction while maintaining clinical efficacy. Its favorable release kinetics and safety profile support its use as an innovative adjuvant therapy for severe OLP."

Clinical • Journal • Dermatology • Dermatopathology • Inflammation • Lichen Planus • Pain

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: Northwestern University | Trial completion date: Jun 2026 ➔ Nov 2026

Trial completion date • Colon Cancer • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Solid Tumor • Ulcerative Colitis

Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Kafrelsheikh University | Trial completion date: May 2025 ➔ Oct 2025 | Trial primary completion date: Apr 2025 ➔ Sep 2025

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Kafrelsheikh University | Trial completion date: May 2025 ➔ Dec 2025 | Trial primary completion date: Apr 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Severe drug-induced liver injury from acipimox and telmisartan co-administration: A case report and review of literature. (PubMed, Medicine (Baltimore)) - "This study is the first to highlight a significant case of severe liver injury resulting from concurrent administration of acipimox and telmisartan, which is potentially influenced by factors such as age, sex, drug interactions, and genetic polymorphisms. This study aimed to emphasize the significance of implementing precise and individualized treatment strategies for managing drug combinations for patients with multiple comorbidities."

Journal • Review • Anorexia • Cardiovascular • Hepatology • Hypertension • Liver Failure

Solubility improvement of atorvastatin using deep eutectic solvents. (PubMed, J Adv Pharm Technol Res) - "The increase in solubility was fairly considerable, allowing ATCH to dissolve at high concentrations in DESs, with a solubility of 0.158 ± 0.098 mg/mL compared to 0.000597 ± 0.003 mg/mL in water. Thus, it is obtainable to conclude that among the selected coformers, the DES system with the potential for improving the solubility of ATCH is DESs with NA coformer assisted by PG."

Journal

Efficacy, safety and cost-effectiveness of 40 mg versus 80 mg atorvastatin in a Sri Lankan cohort with acute coronary syndrome: a protocol for a single-centre randomised controlled clinical trial. (PubMed, Trials) - "This will be the first head-to-head comparison of atorvastatin 40 mg and 80 mg in a South Asian cohort. The findings will provide evidence on efficacy and safety of prescribing atorvastatin 40 mg dose in South Asians with ACS."

Biomarker • Clinical • Clinical protocol • HEOR • Journal • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia

Atorvastatin improves long-term memory by reducing amyloid-β formation and neuronal damage in STZ-induced diabetic rats. (PubMed, J Mol Histol) - No abstract available

Journal • Preclinical • Diabetes • Metabolic Disorders

A randomized controlled trial of the short-term effect of rosuvastatin on the corrected QT interval. (PubMed, Sci Rep) - P=N/A | "This study compared the changes of QTc interval between populations receiving atorvastatin and rosuvastatin, explained the effect of rosuvastatin on QTc interval, and the correlation between rosuvastatin and QT prolongation. Rosuvastatin monotherapy does not appear to increase the risk of arrhythmia. But this study did not assess the usage of rosuvastatin with other QT-prolonging drugs, the potential for an additive effect should be considered when combining rosuvastatin with other QT-prolonging drugs.Trial registration: ChiCTR2400092701 (21/11/2024)."

Clinical • Journal • Cardiovascular

3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitory Activity of Padina pavonia Terpenoids: An Integrated In Vitro and In Silico Exploration. (PubMed, Chem Biodivers) - "Molecular docking revealed that all compounds have affinity toward HMGCR, and compounds 1 and 2 are effectively bound to the same active site as the reference drug atorvastatin...In vitro experiments revealed the inhibitory activity of all isolated terpenes, with compound 1 exhibiting the most potent activity. Therefore, terpenoids of P. pavonia represent promising candidates for the development of HMGCR inhibitors."

Journal • Preclinical • Dyslipidemia • Metabolic Disorders